[CAS NO. 134665-72-8] CNDAChydrochloride
PRODUCTS SPECIFICATIONS [134665-72-8]
DESCRIPTION [134665-72-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 288.69 |
| Molecular Formula | C10H13ClN4O4 |
| SMILES | O=C(N=C(N)C=C1)N1[C@H]2[C@@H](C#N)[C@H](O)[C@@H](CO)O2.Cl |
Summary
CNDAC hydrochloride is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC hydrochloride induces DNA damage and apoptosis [1] [2] .
In Vitro
CNDAC has a unique mechanism of action: after incorporation into DNA, it induces single-strand breaks (SSBs) that are converted into double-strand breaks (DSBs) when cells go through a second S phase
[1]
.
Lack of Rad51D and XRCC3 sensitizes cells to CNDAC (0-1 μM; 24 h)
[1]
.
CNDAC (0-100 μM; 3 days) inhibits proliferation of HL-60 and THP-1 cells
[2]
.
CNDAC (0-10 μM; 3-6 days) induces apoptosis in HL-60 and THP-1 cells
[2]
.
CNDAC (6 μM; 48 h) induces cell cycle arrest in the G2 phase following a delayed S phase in HCT116 cells
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF CHO cells |
| Concentration: | 0-1 μM |
| Incubation Time: | 24 h |
| Result: | Inhibited cell survival with IC 50 s of 0.006, 0.32, 0.48 and 0.0053 μM against Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF cell lines, respectively. |
Cell Proliferation Assay [2]
| Cell Line: | HL-60 and THP-1 cells |
| Concentration: | 0-100 μM |
| Incubation Time: | 3 days |
| Result: | Inhibited proliferation with IC 50 s of 1.5832 μM and 0.84 μM against HL-60 and THP-1 cells, respectively. |
Apoptosis Analysis [2]
| Cell Line: | HL-60 and THP-1 cells |
| Concentration: | 0, 0.5, 1, 2, 3, 4, 5 and 10 μM |
| Incubation Time: | 3, 4, 5, and 6 days |
| Result: | Induced apoptosis in both cells. |
Cell Cycle Analysis [3]
| Cell Line: | HCT116 |
| Concentration: | 6 μM |
| Incubation Time: | 48 h |
| Result: | 36 and 36% of cells were arrested in late-S and G2/M phases, respectively. |
In Vivo
CNDAC (20mg/kg; i.p.; daily for 10 days) shows antitumor activity in mice [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | CDF1 mice, P388 tumor model [4] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection, daily for 10 days |
| Result: | Greatly increased the survival time and survival rate. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 125 mg/mL ( 432.99 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.4639 mL | 17.3196 mL | 34.6392 mL |
| 5 mM | 0.6928 mL | 3.4639 mL | 6.9278 mL |
| 10 mM | 0.3464 mL | 1.7320 mL | 3.4639 mL |
References
- [1] Liu XJ, et al. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chin J Cancer. 2012 Aug;31(8):373-80.
- [2] Jagan S, et al. Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine. Adv Hematol. 2012;2012:727683.
- [3] Serova M, et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36.
- [4] Azuma A, et al. Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. J Med Chem. 1993 Dec 24;36(26):4183-9.